Kerendia 20mg Tablet contains Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist indicated for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes mellitus. Finerenone exerts its therapeutic effect by blocking the mineralocorticoid receptor, thereby reducing inflammation and fibrosis in the kidneys and cardiovascular system. This mechanism helps to slow the progression of kidney damage and reduce the risk of cardiovascular events in patients with CKD and type 2 diabetes. Kerendia is typically prescribed as part of a comprehensive management plan including glycemic control, blood pressure management, and lifestyle modifications. The recommended dosage is one 20mg tablet once daily, with adjustments based on renal function and potassium levels. Patients should be monitored regularly for hyperkalemia and renal function during treatment. Kerendia is contraindicated in patients with hyperkalemia, severe renal impairment, or hypersensitivity to Finerenone. Common adverse effects may include hyperkalemia, hypotension, and dizziness. Kerendia should be used cautiously in patients with risk factors for hyperkalemia and in combination with other potassium-sparing agents. This medication offers a novel therapeutic option for reducing renal and cardiovascular complications in patients with CKD and type 2 diabetes.